top of page
Search
  • Writer's pictureVoisin Céline

More than 450 patients enrolled in the biomarker part of the PIONeeR Project

The RHU PIONeeR Project announces the completion of a major milestone with more than 450 patients enrolled in the biomarker part of the study, led by Veracyte, in early 2023.

The PIONeeR project is the largest biomarker research program ever conducted. It explores more than 400 different parameters in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors. Enrollment in the biomarker study is now completed but remains open in the PIONeeR Project’s umbrella clinical trial, which is evaluating the benefits of multiple treatment combinations in patients with different immune profiles, again with the unique goal of identifying the combination that has the best chance of improving patient survival and quality of life.

We will be back to you on a regular basis with the many expected results of the PIONeeR BIOMARKERS study!

Centres

Nombre de patients screenés

Nombre de patients inclus

Hôpital Nord - Marseille

221

200

Oncopole Toulouse

29

28

CLB Lyon


34

30

Clinique Maymard - Bastia

4

3

Hôpital Européen - Marseille

12

12

Hôpital Saint Joseph - Marseille

40

36

CH Toulon

45

42

CH Aix Pertuis

30

30

CH Bastia

3

3

CH Avignon

18

14

CH Nîmes

13

14

Oncogard

11

11

Cahors

3

3

CHIVA

9

7

Montauban

3

3

Annecy

5

4

CH Villefranche-sur-Saône

15

15

Total

498

455 (101.1% d'inclusions)


0 views0 comments

Comments


bottom of page